中国医学创新
中國醫學創新
중국의학창신
Medical Innovation of China
2015年
27期
139-141
,共3页
晚期肺腺癌%靶向治疗%吉非替尼
晚期肺腺癌%靶嚮治療%吉非替尼
만기폐선암%파향치료%길비체니
Advanced lung adenocarcinoma%Targeted therapy%Gefitinib
目的：分析并探讨晚期肺腺癌靶向治疗的临床效果，为今后的肿瘤治疗方向提供一定的理论依据。方法：选取2010年5月-2014年5月本院呼吸内科收治的72例晚期肺腺癌患者作为研究对象。其中一线治疗22例，二线治疗50例。口服250 mg的吉非替尼，1次/d，服药前后1 h内不能服用其他药物，连续服用直到肿瘤进展或发生不可耐受的副作用。针对骨转移患者提供唑来膦酸、合并脑转移患者提供r刀放射治疗。结果：一线治疗患者中CR 6例，PR 9例，SD 7例，中位缓解时间（7.6±0.5）个月，中位肿瘤进展时间（8.5±0.6）个月，随访4~24个月，中位随访14个月，死亡4例；二线治疗的患者中PR 8例，SD 26例， PD 16例，中位缓解时间（6.5±0.4）个月，中位肿瘤进展时间（7.2±0.5）个月，随访4~30个月，中位随访12个月，8例患者死亡。一线治疗总有效率高于二线治疗，比较差异有统计学意义（P<0.05）。患者出现的不良反应主要为皮疹、皮肤瘙痒以及肝功能损害，且多为1~2度。结论：晚期肺腺癌靶向治疗中，吉非替尼一线治疗优于二线治疗，具有安全性高、副作用小的特点。但价格昂贵，无法完全普及使用。
目的：分析併探討晚期肺腺癌靶嚮治療的臨床效果，為今後的腫瘤治療方嚮提供一定的理論依據。方法：選取2010年5月-2014年5月本院呼吸內科收治的72例晚期肺腺癌患者作為研究對象。其中一線治療22例，二線治療50例。口服250 mg的吉非替尼，1次/d，服藥前後1 h內不能服用其他藥物，連續服用直到腫瘤進展或髮生不可耐受的副作用。針對骨轉移患者提供唑來膦痠、閤併腦轉移患者提供r刀放射治療。結果：一線治療患者中CR 6例，PR 9例，SD 7例，中位緩解時間（7.6±0.5）箇月，中位腫瘤進展時間（8.5±0.6）箇月，隨訪4~24箇月，中位隨訪14箇月，死亡4例；二線治療的患者中PR 8例，SD 26例， PD 16例，中位緩解時間（6.5±0.4）箇月，中位腫瘤進展時間（7.2±0.5）箇月，隨訪4~30箇月，中位隨訪12箇月，8例患者死亡。一線治療總有效率高于二線治療，比較差異有統計學意義（P<0.05）。患者齣現的不良反應主要為皮疹、皮膚瘙癢以及肝功能損害，且多為1~2度。結論：晚期肺腺癌靶嚮治療中，吉非替尼一線治療優于二線治療，具有安全性高、副作用小的特點。但價格昂貴，無法完全普及使用。
목적：분석병탐토만기폐선암파향치료적림상효과，위금후적종류치료방향제공일정적이론의거。방법：선취2010년5월-2014년5월본원호흡내과수치적72례만기폐선암환자작위연구대상。기중일선치료22례，이선치료50례。구복250 mg적길비체니，1차/d，복약전후1 h내불능복용기타약물，련속복용직도종류진전혹발생불가내수적부작용。침대골전이환자제공서래련산、합병뇌전이환자제공r도방사치료。결과：일선치료환자중CR 6례，PR 9례，SD 7례，중위완해시간（7.6±0.5）개월，중위종류진전시간（8.5±0.6）개월，수방4~24개월，중위수방14개월，사망4례；이선치료적환자중PR 8례，SD 26례， PD 16례，중위완해시간（6.5±0.4）개월，중위종류진전시간（7.2±0.5）개월，수방4~30개월，중위수방12개월，8례환자사망。일선치료총유효솔고우이선치료，비교차이유통계학의의（P<0.05）。환자출현적불량반응주요위피진、피부소양이급간공능손해，차다위1~2도。결론：만기폐선암파향치료중，길비체니일선치료우우이선치료，구유안전성고、부작용소적특점。단개격앙귀，무법완전보급사용。
Objective:To analyze and study the clinical effect of targeted therapy in the treatment of advanced lung adenocarcinoma and to provide certain theoretical basis for the future direction of cancer therapy.Method:72 cases of lung adenocarcinoma patients in the respiratory medicine of our hospital from May 2010 to May 2014 were selected as the research objects.22 cases were given first-line treatment,50 cases were given second-line treatment.Patients were given Gefitinib orally at a dose of 250 mg per day and they couldn’t take other drugs within 1 hour before and after drug use.This treatment was continued until the tumor progression or the occurrence of intolerable side effects.Patients with bone metastases were given Zoledronic acid and patients with brain metastasis were given r knife radiotherapy.Result:In the patients with first-line treatment,6 cases were complete remission,9 cases were partial response and 7 cases were stability.The median alleviate time was (7.6±0.5) months,the median tumor progression time was (8.5±0.6) months and the median follow-up was 14 months(4-24 months).4 patients with first-line treatment died.Among the patients with second-line treatment,8 cases were partial response,26 cases were stability and 16 cases were partial response, the median relief time was (6.5±0.4)months,the median tumor progression time was (7.2±0.5) months and the median follow-up was 12 months (4-30 months).8 patients with second-line treatment died.The total effective rate of the first-line treatment was higher than that of the second-line treatment,the difference was statistically significant(P<0.05). The main adverse reactions were rash,pruritic skin and liver function lesion,the extent of degree was mainly 1 to 2 degree.Conclusion:In the targeted therapy of lung adenocarcinoma,Gefitinib with first-line treatment is better than Gefitinib with second line treatment.It has the advantages of high safety and little side effects.But its price is expensive,so it can’t be fully widespread used.
